@article{10902/29875,
year = {2023},
url = {https://hdl.handle.net/10902/29875},
abstract = {Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and predictive biomarkers for immunotherapy responses. In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology and the Spanish Society of Medical Oncology have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice},
organization = {Funding. SEOM and SEAP acknowledge the financial support for this project in the form of unrestricted collaboration in the logistics from AstraZeneca and Roche},
publisher = {Springer-Verlag Italia},
publisher = {Clinical and Translational Oncology, 2023, 25, 1252-1267 - (CORRECTION) 2023, 25, 1488},
title = {New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology},
author = {Isla, Dolores and Lozano, Maria D. and Paz-Ares, Luis and Salas, Clara and Castro, Javier de and Conde, Esther and Felip, Enriqueta and Gómez Román, José Javier and Garrido, Pilar and Enguita, Ana Belén},
}